Surgery – Means for introducing or removing material from body for... – Infrared – visible light – ultraviolet – x-ray or electrical...
Reexamination Certificate
2011-05-10
2011-05-10
Lundgren, Jeffrey S. (Department: 1613)
Surgery
Means for introducing or removing material from body for...
Infrared, visible light, ultraviolet, x-ray or electrical...
C514S690000
Reexamination Certificate
active
07941211
ABSTRACT:
Pre-treatment using a xanthin carotenoid (preferably 3R,3′R-zeaxanthin) can improve the benefits and efficacy of photodynamic therapy (PDT), which uses a light-activated drug (such as verteporfin) in patients who suffer from unwanted retinal blood vessel growth, including the “wet” (exudative) form of macular degeneration. Before a PDT treatment, patients are given a regimen of orally-ingested zeaxanthin for a period of at least 1 and preferably at least 2 to 3 weeks, at dosages of at least 3 and preferably at least 10 milligrams per day. Since zeaxanthin imparts a yellowish color to the macula, a preferred dosage should increase a patient's macular pigment density before the PDT treatment is performed.
REFERENCES:
patent: 3841967 (1974-10-01), Dasek et al.
patent: 3879424 (1975-04-01), Surmatis et al.
patent: 3891504 (1975-06-01), Schocher et al.
patent: 3920834 (1975-11-01), Klaui et al.
patent: 3932462 (1976-01-01), Goetz et al.
patent: 3951743 (1976-04-01), Shepherd et al.
patent: 3954804 (1976-05-01), Fischer et al.
patent: 3974181 (1976-08-01), Surmatis et al.
patent: 4078094 (1978-03-01), Katzen
patent: 4153615 (1979-05-01), Saucy
patent: 4298621 (1981-11-01), Samis et al.
patent: 4405417 (1983-09-01), Grass et al.
patent: 4522743 (1985-06-01), Horn et al.
patent: 4579973 (1986-04-01), Widmer et al.
patent: 4726955 (1988-02-01), Horn et al.
patent: 4851339 (1989-07-01), Hills
patent: 4935409 (1990-06-01), Wollweber et al.
patent: 4952716 (1990-08-01), Lukac et al.
patent: 5180747 (1993-01-01), Matsuda
patent: 5227507 (1993-07-01), Lukac et al.
patent: 5242950 (1993-09-01), Hastings
patent: 5290605 (1994-03-01), Shapira
patent: 5308759 (1994-05-01), Gierhart
patent: 5310764 (1994-05-01), Baranowitz et al.
patent: 5350773 (1994-09-01), Schweikert et al.
patent: 5356636 (1994-10-01), Schneider et al.
patent: 5360730 (1994-11-01), Orndorff et al.
patent: 5382714 (1995-01-01), Khachik
patent: 5386063 (1995-01-01), Khachik et al.
patent: 5427783 (1995-06-01), Gierhart
patent: 5429939 (1995-07-01), Misawa et al.
patent: 5437997 (1995-08-01), Liao et al.
patent: 5523494 (1996-06-01), Torres-Cardona et al.
patent: 5527533 (1996-06-01), Tso et al.
patent: 5607839 (1997-03-01), Tsubokura et al.
patent: 5684238 (1997-11-01), Ausich et al.
patent: 5777173 (1998-07-01), Paust et al.
patent: 5780693 (1998-07-01), Bernhard et al.
patent: 5871766 (1999-02-01), Hennekens
patent: 6218436 (2001-04-01), Howard et al.
patent: 6443976 (2002-09-01), Flower et al.
patent: 2003/0002014 (2003-01-01), Grant
patent: 2004/0087664 (2004-05-01), Marcus et al.
patent: 2004/0176345 (2004-09-01), Lavie
patent: 0 747 483 (1996-12-01), None
patent: WO 96/40092 (1996-12-01), None
Thomas Ciulla, et al, Changing Therapeutic Paradigms for Exudative Age-related Macular Degeneration: Antiangiogenic Agents and Photodynamic Therapy, 8 Exp. Opin. Invest. Drugs 2173 (1999).
Paul Bernstein & Nikita Katz, The Role of Ocular Free Radicals in Age-Related Macular Degeneration, 20 Cut. Ocular Toxicol. 141, 163-73 (2001).
D.W. Harkin, et al, Reperfusion Injury is Greater with Delayed Restoration of Venous Outflow in Concurrent Arterial and Venous Limb Injury, 87 Br. J Surg. 734 (2000).
Bendich, A., et al, “Biological actions of carotenoids,” FASEB Journal 3: 1927-1932 (1989).
Bone, R.A., et al, “Preliminary identification of the human macular pigment,” Vision Res. 25: 1531-1535 (1985).
Bone R.A., et al, “Stereochemistry of the macular carotenoids,” Invest. Ophthalmol. Vis. Sci. 34: 2033-2040 (1993).
Columbo, V.E., et al, “Structures and properties of stabilized vitamin and carotenoid dry powders,” Food Structure 10: 161-170 (1991).
di Mascio, P., et al, “Lycopene as the most efficient biological carotenoid singlet oxygen quencher,” Archives of Biochemistry and Biophysics 274: 532-538 (1989).
di Mascio, P., et al, “Antioxidant defense systems: the role of carotenoids, tocopherols, and thiols,” Am. J. Clin. Nutr. 53: 194S-200S (1991).
Dorey, C.K., et al, “Lipofuscin in aged and AMD eyes,” in Retinal Degeneration (Hollyfield et al., editors, Plenum Press, New York, 1993).
Eye Disease Case Control Study Group, “Antioxidant status and neovascular age-related macular degeneration,” Arch. Ophthalmol. 11: 104-109 (1993).
Gerster, H., “Review: antioxidant protection of the aging macula,” Age and Aging 20: 60-69 (1991).
Haegerstrom-Portnoy, G., “Short-wavelength-sensitive-cone sensitivity loss with aging: a protective role for macular pigment?,” J. Opt. Soc. Am. A5: 2140-2144 (1988).
Handelman, G.J. and Dratz, E.A., “The role of antioxidants in the retina and retinal pigment epithelium and the nature of prooxidant-induced damage,” Adv. in Free Radical Biology & Medicine 2: 1-23 and 55-57 (1986).
Handelman, G.J., et al, “Carotenoids in the human macula and whole retina,” Invest. Ophthalmol. Vis. Sci. 29: 850-855 (1988).
Malinow, M.R., et al, “Diet-related macular anomalies in monkeys,” Invest. Ophthalmol. Vis. Sci. 19: 857-863 (1980).
National Advisory Eye Council, Vision Research: A National Plan, 1994-1998 (NIH Publication 93-3186), pp. 55-64, 336, and 356(1998).
Seddon, J.M., et al, “Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration,” JAMA 272: 1413-1420 (1994).
Sperduto, R.D., et al, “Do we have a nutritional treatment for age-related cataract or macular degeneration?,” Arch. Ophthalmol. 108: 1403-1405 (1990).
Taylor, A., et al, “Oxidation and aging: impact on vision,” Journal of Toxicology and Industrial Health 9:349-371 (1993).
“Flora-Glo Lutein” product specification sheets (Kemin Industries Inc., Des Moines, Iowa, 1997).
Alpers, J.R., et al, “Serum Carotenoids and Age-Related Macular Degeneration,” Invest Ophthalmol Vis Sci 36: S9 (1995).
Ascherio, A., et al, “Correlations of Vitamin A and E Intakes with the Plasma Concentrations of Carotenoids and Tocopherols among American Men and Women,” J of Nutrition 122 (9): 1792-1801 (1992).
Bertram, J.S., et al, “Diverse carotenoids protect against chemically induced neoplastic transformation,” Carcinogenesis 12 (4): 671-678 (1991).
Blumenkranz, M.S., et al, “Risk factors in age-related maculopathy complicated by choroidal neovascularization,” Ophthalmology 93: 552-558 (1986).
Bone, R.A., et al, “Distribution of macular pigment stereomers in individual eyes, including those with age-related macular degeneration (AMD),” Arvo Abstracts Invest Ophthalmol Vis Sci V.35: 4 pp 1502 (1994).
Bone, R.A., et al, “Analysis of the macular pigment by HPLC: retinal distribution and age study,” Invest Ophthalmol Vis Sci 29: 843-9 (1988).
Bone, R.A., “The role of the macular pigment in the detection of polarized light,” Vision Research 30: 213-220 (1979).
Bowmaker, J.D., et al, “Visual pigments and oil droplets in genetically manipulated and carotenoid deprived quail: a microspectrophotometric study,” Vision Res 33: 571-578 (1993).
Burton, G.W., “Antioxidant action of carotenoids,” American Institute of Nutrition, 109-111 (1988).
Castorina, C., et al, “Lipid peroxidation and antioxidant enzymatic systems in rat retina as a function of age,” Neurochem Res 17(6): 599-604 (1992).
Christen, W.G., “Antioxidants and eye disease,” The Amer J of Medicine 97 (suppl 3A): 3A-142-3A-162 (1994).
Conn, P.F., et al, “The singlet oxygen and carotenoid interaction,” J Photochem Photobiol B Biol 11: 41-47 (1991).
Crary, E.J., “Antioxidant treatment of macular degeneration of the aging and macular edema in diabetic retinopathy,” Southern Med J 80: 38 (1997).
Fite, K.V., “Drusen-like deposits in the outer retina of Japanese quail,” Exp Eye Res 59: 417-424 (1994).
Fite, K.V., et al, “Experimental light damage increases
Basquill Sean
Lundgren Jeffrey S.
Nixon & Peabody LLP
ZeaVision, LLC.
LandOfFree
Preloading with macular pigment to improve photodynamic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preloading with macular pigment to improve photodynamic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preloading with macular pigment to improve photodynamic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2634469